Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
St John'S University is currently managing a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which represents the entirety of the university's current active engagement with the patent office. This concentration suggests a highly specific technical focus for the university's current prosecution efforts, likely targeting a core innovation or a narrow range of biological or pharmaceutical processes.
The prosecution activity is limited to 1 distinct art unit, indicating that the intellectual property being sought is confined to a narrow regulatory or technical classification. GALSTER, SAMUEL LEONARD is identified as the busiest examiner for this portfolio. This individual is responsible for the busiest examiner pending count, making them the primary point of contact for the university's pending matters.
For a patent practitioner, this point of contact means that the outcome of the university's current prosecution depends entirely on the interactions with this examiner. The lack of diversity in distinct examiners or art units reflects a streamlined but centralized risk profile. Success in this technology area will require navigating the specific preferences and historical tendencies of the assigned art unit to ensure the pending action reaches a favorable conclusion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689742 | INJECTABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689742 | INJECTABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689742 | INJECTABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSt John'S University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samuel Leonard Galster has the most, with 1 of St John'S University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
